Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.

ABSTRACT:

Context

Docosahexaenoic acid (DHA) is the most abundant long-chain polyunsaturated fatty acid in the brain. Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology.

Objective

To determine if supplementation with DHA slows cognitive and functional decline in individuals with Alzheimer disease.

Design, setting, and patients

A randomized, double-blind, placebo-controlled trial of DHA supplementation in individuals with mild to moderate Alzheimer disease (Mini-Mental State Examination scores, 14-26) was conducted between November 2007 and May 2009 at 51 US clinical research sites of the Alzheimer's Disease Cooperative Study

SUBMITTER: Quinn JF 

PROVIDER: S-EPMC3259852 | biostudies-literature | 2010 Nov

REPOSITORIES: biostudies-literature